Serradeil-Le Gal, C; Wagnon, J; Valette, G; Garcia, G; Pascal, M; Maffrand, JP; Le Fur, G (2002). „Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands”. Progress in brain research. Progress in Brain Research. 139: 197—210. ISBN978-0-444-50982-6. PMID12436936. doi:10.1016/S0079-6123(02)39017-4.
Lemmens-Gruber, R; Kamyar, M (2006). „Vasopressin antagonists”. Cellular and molecular life sciences : CMLS. 63 (15): 1766—79. PMID16794787. doi:10.1007/s00018-006-6054-2.
Decaux, G; Soupart, A; Vassart, G (2008). „Non-peptide arginine-vasopressin antagonists: the vaptans”. Lancet. 371 (9624): 1624—32. PMID18468546. doi:10.1016/S0140-6736(08)60695-9.
Serradeil-Le Gal, C; Wagnon, J; Valette, G; Garcia, G; Pascal, M; Maffrand, JP; Le Fur, G (2002). „Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands”. Progress in brain research. Progress in Brain Research. 139: 197—210. ISBN978-0-444-50982-6. PMID12436936. doi:10.1016/S0079-6123(02)39017-4.
Lemmens-Gruber, R; Kamyar, M (2006). „Vasopressin antagonists”. Cellular and molecular life sciences : CMLS. 63 (15): 1766—79. PMID16794787. doi:10.1007/s00018-006-6054-2.
Decaux, G; Soupart, A; Vassart, G (2008). „Non-peptide arginine-vasopressin antagonists: the vaptans”. Lancet. 371 (9624): 1624—32. PMID18468546. doi:10.1016/S0140-6736(08)60695-9.